通过无柱免疫细胞磁分选工作流程从 TCR α/ß+中分离TCR γ/δ+

近年来 T 细胞受体 (TCR) 细胞疗法因其为癌症和感染性疾病提供一系列可能性的治疗而获得广泛关注。由于γδ T细胞被视为对癌症免疫治疗颇有潜力的区域细胞,基于γδ T细胞的新型免疫疗法正在被大力开发。尽管TCR疗法在研发、生产及临床应用等领域已经取得重大进展,但 TCR细胞疗法的开发在功效及安全性方面仍然面临很多挑战。 MARS® 平台为优化和扩大 γδ T细胞的研发和生产提供了一种简单而又全新的方法和工具,可以帮助TCR 疗法最大化的发挥临床潜力。

TCR γ/δ+ separation from TCR α/ß+ with MARS® Bar

Application note highlighting benefits of TCR γ/δ+ separation from TCR α/ß+ with Applied Cells MARS Bar

In recent years T cell receptor (TCR) cell therapy has gained popularity due to a range of possible treatments for cancer and some infectious diseases it could provide. Since γδ T-cells constitute promising effector cell compartments for cancer immunotherapy, novel γδ T-cell-based immunotherapies are being developed. Although advancements in TCR engineering, manufacturing, and clinical applications have led to […]